SCHEMBL4675136

SCHEMBL4675136

COc1cccc(Sc2cocc2C(=O)C=C(O)c2nc[nH]n2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
KMT2A Q03164 1/20 0.37
EDNRA P25101 2/20 0.36
HSP90AA1 P07900 1/20 0.36
IDO1 P14902 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
PDE4B Q07343 1/20 0.34
NOTUM Q6P988 1/20 0.34
EGLN1 Q9GZT9 1/20 0.34
FGFR4 P22455 1/20 0.34
MTNR1A P48039 2/20 0.33
MTNR1B P49286 2/20 0.33
TERT O14746 1/20 0.33
LMNA P02545 1/20 0.33
DHFR P00374 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673116 0.88 MMP2 (0.34) MEN1NPC1KMT2AIDO1KDM4E
SCHEMBL4675243 0.87 MEN1 (0.35) MEN1KMT2AIDO1PDE4BNOTUM
SCHEMBL4675083 0.84 SLC6A2 (0.34) MEN1KMT2ASIRT2NOTUMLMNA
SCHEMBL4676454 0.83 EDNRA (0.38) MEN1NPC1KMT2AEDNRAHSP90AA1
SCHEMBL4672706 0.83 EDNRA (0.36) MEN1NPC1KMT2AEDNRASIRT2
SCHEMBL4670808 0.82 ALDH1A1 (0.33) LMNAKDM4EALDH1A1HPGDL3MBTL1
SCHEMBL4676271 0.82 EDNRA (0.38) MEN1NPC1KMT2AEDNRASIRT2
SCHEMBL4672407 0.82 KDM4E (0.45) MEN1NPC1KMT2AHSP90AA1LMNA
SCHEMBL4672577 0.82 HAO1 (0.35) MEN1KMT2AIDO1MTNR1AMTNR1B
SCHEMBL4672853 0.81 EDNRA (0.36) MEN1NPC1KMT2AEDNRASIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 MEN1 4663/4885NPC1 934/4885KMT2A 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.